Arthur G. Mikaelian

Founder, CEO & President at MedoLife

For the past 20 years Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of nutraceuticals and pharmaceutical drugs, as well as expanding his interests in cancer and oncology.

One of Dr. Mikaelian’s greatest scientific contributions and ground-breaking inventions is his Polarization technology which targets key elements in the main ingredients of medications, leading to the intensification of potency of liquid or solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it.

Dr. Mikaelian’s technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy.

Timeline

  • Founder, CEO & President

    Current role

View in org chart